Navigation Links
EPIX Pharmaceuticals Announces Statistically Significant Results in,Cognitive Function from Phase 1b Clinical Trial of Novel 5-HT6 Drug,Candidate

ne month period than subjects on placebo.

"We are very pleased with the tolerability and pro-cognitive effects observed in this Phase 1b clinical trial of PRX-07034," said Michael G. Kauffman, M.D., Ph.D., chief executive officer, EPIX Pharmaceuticals. "These data support plans to initiate further clinical trials to evaluate the efficacy of PRX-07034 in obesity, cognitive impairment associated conditions, or both. We will continue to evaluate the data and provide an update on our plans in the coming months."

Dr. Kauffman added, "We are continuing to advance our pipeline of proprietary drug candidates and look forward to our next milestone - obtaining the results from our ongoing Phase 2a trial of PRX-08066 in pulmonary hypertension associated with chronic obstructive pulmonary disease, which we expect mid-year."

These results were announced this morning in an oral presentation by Kimberley S. Gannon, Ph.D., senior director of biology for EPIX, at the "ALZHEIMER'S DISEASE: From Molecular Mechanisms to Drug Discovery" conference in Punta Cana, Dominican Republic.

About PRX-07034

PRX-07034 is a novel, highly selective, small-molecule antagonist of a specific G-protein coupled receptor (GPCR) known as 5-HT6, which was discovered by EPIX using its proprietary in silico drug discovery platform. PRX-07034 has shown cognitive-enhancing properties in preclinical animal models of memory impairment, as well as reductions of both food intake and body weight in several preclinical animal models of obesity. The human 5-HT6 receptor is found predominantly in the central nervous system with little or no expression in peripheral tissues, which may result in fewer peripheral side effects.

About CogScreen(TM)

CogScreen(TM) is a widely used tool that encompasses a battery of tests originally designed to assess memory and cognition in normal individuals with demonstrated utility in
'"/>




Page: 1 2 3 4

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:11/21/2014)... Calif. , Nov. 20, 2014  Edwards Lifesciences ... in the science of heart valves and hemodynamic monitoring, ... giving in 2014 to support a strong launch of ... Matters , and to improve the global communities where ... 2014, Edwards, global corporate giving will exceed $8 million, ...
(Date:11/21/2014)... , Nov. 20, 2014 /CNW Telbec/ - KLOX Technologies ... the following appointments: Todd Martensen ... the newly created role of Chief Commercial Officer, to ... using topical photoconverter gel for the treatment of chronic ... traumatic wounds, recently approved in Europe ...
(Date:11/21/2014)... Fla. , Nov. 20, 2014   Coqui ... become the first U.S. commercial producer of Molybdenum-99 (Mo-99), ... contract with INVAP to design its Medical ... Mo-99 is the parent isotope of Technetium-99, ... procedures worldwide. In 2012, Congress passed legislation making it ...
Breaking Medicine Technology:Edwards Lifesciences Increases Charitable Giving In 2014 To Support Launch Of Every Heartbeat Matters 2KLOX Technologies announces executive appointments 2KLOX Technologies announces executive appointments 3KLOX Technologies announces executive appointments 4Coqui RadioPharmaceuticals Inks Deal With INVAP 2
... 2010 United Seating & Mobility (USM) , one ... excited to announce today that it has finalized a transaction ... The transaction applies to Fridley, MN serving the greater ... and Appleton, WI; RehabTECH will continue to operate its Illinois ...
... Dec, 2, 2010 SRI International, an independent ... it is collaborating with PhenoMatriX (PMX), a biotechnology ... drugs such as cisplatin and related analogues are ... have served as major weapons against solid tumors ...
Cached Medicine Technology:SRI International and PhenoMatriX Collaborate to Develop Platin-Based Chemotherapies 2SRI International and PhenoMatriX Collaborate to Develop Platin-Based Chemotherapies 3SRI International and PhenoMatriX Collaborate to Develop Platin-Based Chemotherapies 4
(Date:11/22/2014)... Greenville, Sc (PRWEB) November 23, 2014 ... officially opened its doors in the downtown Greenville area. ... of Downtown Greenville , decided to open her own ... such amazing results with the patients. , AlignLife ... the proper tools. With a focus on chiropractic care ...
(Date:11/22/2014)... 2014 PrettyTailor , an outstanding ... new big promotion. Customers can buy new dresses at ... can visit its website. , As a matter of ... dresses. It mainly provides four types of wedding outfits, ... flower girl dresses. It also provides a variety of ...
(Date:11/22/2014)... (PRWEB) November 23, 2014 A classic black ... of the most famous dress suppliers, has unveiled its new ... new dresses are now offered at a big discount, up ... special offer. , The new black prom dresses, made ... order to meet the needs of all customers, the company ...
(Date:11/22/2014)... 2014 BambooFlooringChina.com is a famous ... proudly released its new collection of bamboo mats ; ... to 29% off. , According to the sales ... grass, making it a highly renewable resource. Their bamboo mats ... mixing color which comes from natural bamboo with caramel bamboo ...
(Date:11/22/2014)... New York, NY (PRWEB) November 22, 2014 ... Australia’s Therapeutics Goods Administration (TGA) approved it for ... Glutathione was approved and listed within the Therapeutic ... http://www.comlaw.gov.au/Details/F2014L01277 , Kyowa Hakko’s Setria® Glutathione ... Chem, a biotech specialist that sources and imports ...
Breaking Medicine News(10 mins):Health News:AlignLife of Downtown Greenville is Now Open and Accepting New Patients 2Health News:Customers Are Welcome to Shop at PrettyTailor.com 2Health News:New Black Prom Dresses from BellasDress.com 2Health News:Trendy Bamboo Mats Online Now By BambooFlooringChina.com 2Health News:Setria® Glutathione Now Available in Australia 2Health News:Setria® Glutathione Now Available in Australia 3
... Childhood cancer survivors diagnosed later with non-melanoma skin cancer ... tumor within 15 years, according to research led by ... percent of survivors in this Childhood Cancer Survivor Study ... skin cancer developed another more aggressive cancer within 15 ...
... June 2010 Elsevier, a world-leading healthcare and ... an agreement with Tarrytown, New York based InfoDesk ... for pharmaceutical and life science companies. The ... technological know-how paves the way for the development ...
... available in German . Early detection is ... every lump turns out to be a malignant tumor. To ... a biopsy and examine the removed tissue under the microscope. ... but also highly time consuming. Research scientists at the Fraunhofer ...
... 8, 2010) A University of Minnesota study definitively shows ... an increased life expectancy. The research is published in the ... The findings stem from the Program on Surgical Control ... at the University of Minnesota in 1975. Researchers evaluated 838 ...
... unique study with sunitinib suggest that it might be ... to treat HIV-positive cancer patients to achieve therapeutic benefit. ... treat their HIV, much more or considerably less chemotherapy ... NCI-supported AIDS Malignancy Consortium (AMC). The trial design ...
... 2010 The Institute for Research in Immunology and ... a new research funding model that brings together the ... accelerate the discovery of new anti-cancer therapeutics. Inspired by ... athletes at the Vancouver Winter Olympics, B2Discovery,s mission is ...
Cached Medicine News:Health News:Non-melanoma skin cancer may help identify survivors at increased risk for future cancers 2Health News:Elsevier and InfoDesk collaborate to co-develop federated drug pipeline intelligence solution 2Health News:Detecting tumors faster 2Health News:Consortium seeks best treatment for HIV-positive cancer patients 2Health News:Consortium seeks best treatment for HIV-positive cancer patients 3Health News:B2Discovery: Entrepreneurs and researchers join forces to conquer cancer 2
... Activins are polypeptide hormones which belong ... superfamily. The TGF- superfamily is a ... which control many aspects of development, ... Other members incude TGF-s, bone morphogenetic ...
... also known as bone Gla protein, is ... is a major component of the noncollagenous ... osteoblasts in bone, with a small amount ... chondrocytes [1]. During bone formation, newly synthesized ...
... Insulin-like growth factor binding protein-2 (IGFBP-2) is ... have been proposed) which specifically bind and ... The binding affinity of IGFBP-2 for IGF-II ... for IGF-I [1], suggesting a role in ...
... suppress the secretion of FSH (follicle stimulating ... two distinct chains, or subunits (alpha and ... the alpha-subunit and betaA-subunit. Inhibin B consists ... dimeric forms of the molecule, containing both ...
Medicine Products: